Valuation : Crinetics Pharmaceuticals

Market Cap 9.01B 7.76B 7.29B 6.66B 12.47B 851B 12.51B 86.18B 33.41B 436B 33.83B 33.09B 1,408B P/E 2026 *
-18.5x
P/E 2027 * -20.6x
Enterprise Value 8B 6.89B 6.48B 5.92B 11.08B 756B 11.11B 76.56B 29.68B 388B 30.06B 29.4B 1,251B EV / Sales 2026 *
49.5x
EV / Sales 2027 * 46.6x
Free-Float
-
Yield 2026 *
-
Yield 2027 * -
1 day+0.13%
1 week+0.13%
1 month+1.30%
3 months+145.31%
6 months+115.01%
Current year+82.49%
1 week 84.92
Extreme 84.92
85.01
1 month 83.86
Extreme 83.86
85.01
Current year 32.3
Extreme 32.3
85.01
1 year 32.3
Extreme 32.3
85.01
3 years 15.76
Extreme 15.76
85.01
5 years 15.23
Extreme 15.23
85.01
10 years 10.63
Extreme 10.63
85.01
Manager TitleAgeSince
President 57 2026-08-31
Corporate Secretary - 2026-08-31
Director TitleAgeSince
Director/Board Member 57 2026-08-31
Date Insider Type Main position Quantity % Market Cap. Importance
9/1/26 Issuer sale

Chief Financial Officer

-209,427 0.1986%
9/1/26 Issuer sale

Founder

-905,240 0.8585%
9/1/26 Issuer sale

Chairman

-232,151 0.2202%

Financials

2026 *2027 *
Net sales 162M 139M 131M 120M 224M 15.29B 225M 1.55B 600M 7.84B 608M 594M 25.29B 180M 155M 145M 133M 248M 16.97B 249M 1.72B 666M 8.69B 674M 659M 28.05B
Net income -447M -385M -362M -331M -619M -42.26B -621M -4.28B -1.66B -21.66B -1.68B -1.64B -69.87B -470M -405M -380M -348M -651M -44.44B -653M -4.5B -1.74B -22.78B -1.77B -1.73B -73.47B
Net Debt -1.01B -866M -813M -744M -1.39B -95B -1.4B -9.62B -3.73B -48.69B -3.78B -3.69B -157B -647M -557M -523M -479M -895M -61.14B -898M -6.19B -2.4B -31.33B -2.43B -2.38B -101B
Logo Crinetics Pharmaceuticals
Crinetics Pharmaceuticals, Inc. is a clinical-stage pharmaceutical company focused on the discovery, development and commercialization of therapeutics for rare endocrine diseases and endocrine-related tumors. Its lead development candidate, PALSONIFY (paltusotine), is the first investigational once-daily, oral, selective somatostatin receptor type 2 (SST2) nonpeptide agonist that is in clinical development for acromegaly and carcinoid syndrome associated with neuroendocrine tumors. Its second product candidate is Atumelnant, which is in clinical development for congenital adrenal hyperplasia (CAH) and patients with either Cushing's disease or Ectopic ACTH Syndrome (EAS). Its drug candidates are orally delivered, small molecule new chemical entities resulting from in-house drug discovery efforts, including other programs addressing a variety of endocrine conditions such as hyperparathyroidism, polycystic kidney disease, Graves' disease, thyroid eye disease, diabetes and obesity.
Employees
594
Sector
-
Date Price Change Volume
26-08-31 US$84.95 +0.13% 8,208,422
26-08-28 US$84.84 -0.01% 1,127,886
Trader
Investor
-
Global
-
Quality
-
ESG MSCI
BBB
  1. Stock Market
  2. Stocks
  3. CRNX Stock